为解决特发性炎性肌病（IIM）中 B 细胞相关致病机制及治疗靶点问题，研究人员开展了通过抑制 JAK/STAT 通路来调节 IIM 中 IL-21 驱动的 B 细胞反应的研究。结果发现托法替尼（Tofacitinib）能有效抑制 B 细胞增殖、分化和（自身）抗体产生，为 IIM 治疗提供新方向。

Golidocitinib is currently the first and only Janus kinase 1 (JAK1) selective inhibitor being evaluated for the treatment of r/r PTCL. In June 2024, golidocitinib was approved by the National Medical ...

Dizal announces new findings on golidocitinib; to present clinical results at ELCC 2025 in Paris on March 26-29: Shanghai Saturday, March 22, 2025, 17:00 Hrs [IST] Dizal, a biopha ...

The study suggests that disturbances in the JAK-STAT signalling pathway, an important communication pathway in the body, may contribute to this side effect. Read the full story here.

Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering. The "Janus Kinase (JAK) ...

ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of ...